News
News
- Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
03/23/2022 / 01:30 - GlobeNewswire - Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering
03/22/2022 / 14:29 - GlobeNewswire - CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering
03/22/2022 / 12:38 - GlobeNewswire - Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases
03/22/2022 / 12:00 - GlobeNewswire - HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer
03/22/2022 / 12:00 - GlobeNewswire - BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction
03/22/2022 / 10:00 - GlobeNewswire - Statera Biopharma Announces Proposed Underwritten Public Offering
03/21/2022 / 21:50 - GlobeNewswire - Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
03/21/2022 / 12:00 - GlobeNewswire - Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
03/17/2022 / 21:02 - GlobeNewswire - Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit
03/17/2022 / 12:00 - GlobeNewswire
Real-time